- Home
- KULR vs MXCT Comparison
KULR vs MXCT Comparison
Compare KULR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KULR | MXCT |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.0M | 160.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KULR | MXCT |
|---|---|---|
| Price | $3.45 | $1.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $7.50 |
| AVG Volume (30 Days) | ★ 1.6M | 704.8K |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $16,677,036.00 | ★ $34,419,000.00 |
| Revenue This Year | $64.40 | N/A |
| Revenue Next Year | $105.13 | $10.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.92 | N/A |
| 52 Week Low | $2.15 | $1.26 |
| 52 Week High | $31.84 | $5.20 |
Technical Indicators
Market Signals| Indicator | KULR | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 45.57 |
| Support Level | $2.93 | $1.48 |
| Resistance Level | $3.69 | $1.59 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 53.57 | 25.00 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.